Kyoto-based Toregem BioPharma has raised $5.3 million in a Pre-Series C round to advance human trials of its tooth-regrowing drug TRG-035, backed by investors including JIC Venture Growth Investments.
Amount Raised
$5.3 Million
Round Type
Series C
Investors
Description
Toregem BioPharma has secured approximately $5.3 million in funding to support Phase II clinical trials of its experimental drug, TRG035, in Japan. The funding brings the company's total support to over $29 million. The Pre-Series C round featured participation from existing and new investors. The clinical trials aim to evaluate the safety and efficacy of the tooth-regeneration therapy.
Quick answer
Toregem BioPharma raised $5.3 Million in a Series C round, dated May 30, 2026. Investors: Chushin Venture Capital, Siif Impact Capital, Shofu, Bi Holdings, Osaka University Venture Capital and JIC Venture Growth Investments. Toregem BioPharma is based in Kyoto, Kyoto Prefecture, Japan.
- How much did Toregem BioPharma raise?
- Toregem BioPharma raised $5.3 Million in a Series C round on May 30, 2026.
- Who invested in Toregem BioPharma?
- Chushin Venture Capital, Siif Impact Capital, Shofu, Bi Holdings, Osaka University Venture Capital and JIC Venture Growth Investments are named as investors in this round.
- What does Toregem BioPharma do?
- Toregem BioPharma is a Japanese biotechnology firm focused on developing TRG-035, the world's first tooth-regeneration therapy.
- Where is Toregem BioPharma based and how big is it?
- Toregem BioPharma is based in Kyoto, Kyoto Prefecture, Japan.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Toregem BioPharma that raised within 45 days of this round, from Fundz verified event records.
- ALZpath raised $8.4M on July 14, 2026.
- HTG Medical raised $513K (Seed) on July 14, 2026.
- Draig Therapeutics raised $65M (Series B) on July 14, 2026.
- Chai Discovery raised $400M (Series C) on July 14, 2026.
- Decode Health raised $1.9M (Grant) on July 14, 2026.
- Precision Peptide Company raised $883K (Seed) on July 14, 2026.
Who to call at Toregem BioPharma, and when
A new round usually means Toregem BioPharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Toregem BioPharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Toregem BioPharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Toregem BioPharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Toregem BioPharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Toregem BioPharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.